Gilead revenue and profit dips due to drop in Harvoni and Sovaldi sales

2 November 2016
2019_biotech_test_vial_discovery_big

US biotech major Gilead Sciences (Nasdaq: GILD) has reported reduced third-quarter 2016 revenue and profit compared to the same period in 2015.

Total revenue for the quarter was $7.5 billion, a 9.6% drop on the $8.3 billion of the third quarter a year ago, and net income was down by 28% from $4.6 billion to $3.3 billion.

Diluted earnings per share dropped to $2.49 from the $3.06 of the previous year and quarterly profit excluding one-time items was $2.75 per share, below the predictions of analysts which averaged $2.85.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology